![Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with MRIdian MR-Guided Radiation Therapy | Markets Insider Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with MRIdian MR-Guided Radiation Therapy | Markets Insider](https://mma.prnewswire.com/media/584686/Overall_Survival_Pancreas_Graph_Infographic.jpg)
Early Clinical Data Suggests Nearly 2X Prolonged Median Survival for Inoperable, Locally Advanced Pancreatic Cancer with MRIdian MR-Guided Radiation Therapy | Markets Insider
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/0b732d25-37b7-4d93-ad0b-8f60f96a958e/gr1.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study | Anticancer Research Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/42/9/4603/F1.large.jpg)
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study | Anticancer Research
![Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017 Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017](https://journals.sagepub.com/cms/10.1177/0272989X16655341/asset/images/large/10.1177_0272989x16655341-fig3.jpeg)
Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients - Mette L. Lousdal, Ivar Sønbø Kristiansen, Bjørn Møller, Henrik Støvring, 2017
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig1_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum](https://discourse.datamethods.org/uploads/default/original/2X/7/75bb0160b856873819cdcefe4dc6072ed7ef267c.png)
Interpreting Survival Probability in Relation to 'Number at Risk' and Median Follow-Up Times - interpret - Datamethods Discussion Forum
![Using median survival in meta-analysis of experimental time-to-event data | Systematic Reviews | Full Text Using median survival in meta-analysis of experimental time-to-event data | Systematic Reviews | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13643-021-01824-0/MediaObjects/13643_2021_1824_Fig5_HTML.png)